Ardelyx, Inc. (ARDX) is in Healthcare, Biotechnology, based in United States, listed on NasdaqGM. Market cap 844.27M USD. 52-week range 3.18 to 8.40 USD. Data as of 2026-10-09.
Ardelyx, Inc. discovers, develops, and commercializes medicines to treat unmet medical needs in the United States and internationally. The company offers IBSRELA, a minimally absorbed small molecule therapy for the treatment of patients with irritable bowel syndrome with constipation; and XPHOZAH, a phosphate absorption inhibitor to reduce serum phosphorus in adults with chronic kidney disease on dialysis. Ardelyx, Inc. was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in ...